BCC5548
CWHM-12
CWHM-12 is a potent inhibitor of <b>αV integrins</b> with <b>IC<sub>50</sub></b>s of 0.2, 0.8, 1.5, and 1.8 nM for <b>αvβ8</b>, <b>αvβ3</b>, <b>αvβ6</b>, and <b>αvβ1</b>.
BCC3590
Cyclo (-RGDfK)
Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM.
BCC3945
BIO 1211
Selective <span class='symbol'>α</span><sub>4</sub><span class='symbol'>β</span><sub>1</sub> (VLA-4) inhibitor
BCC3942
Cilengitide
Cilengitide, a cyclic RGD-containing peptide, is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50s of 4 and 79 nM, respectively.
BCC4266
TR-14035
TR-14035 is a a dual alpha4beta7(IC50=7 nM)/alpha4beta1 (IC50=87 nM) integrin antagonist .
BCC3944
A 205804
A-205804 is an orally bioavailable, potent and selective lead inhibitor of E-selectin and ICAM-1 expression, with an IC50 of 20 nM and 25 nM for E-selectin and ICAM-1, respectively. A-205804 can be used in the research of chronic inflammatory diseases.
BCC3946
A 286982
Potent inhibitor of the LFA-1/ICAM-1 interaction
BCC6080
TCS 2314
TCS 2314 (compound 3) is orally active and selective very late antigen-4 (VLA-4, α4β1, CD49d/CD29) antagonist with an IC50 of 4.4 nM.
BCC7694
RGDS peptide
Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function, decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS and MMP-9.
BCC5349
RGD (Arg-Gly-Asp) Peptides
RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
